Dr. MacElrevey has 11 years of experience in DMPK in preclinical (GLP and non-GLP) and clinical (all phases) settings. She specializes in NCA-based PK, and has worked across a broad range of therapeutic areas, including oncology. She has characterized PK, including assessments of linearity, dose proportionality, bioavailability, etc., for a wide variety of molecules, with a particular interest in biologics drawn from her graduate training in structural biology. She has additional expertise in the design and execution of radio-labeled ADME studies performed in a preclinical setting, including mass balance, tissue distribution (WBA and traditional), and metabolite profiling. She has worked in CRO and consulting environments, with an eye toward regulatory compliance and customer service.